89 search results for: symposium
ACG 2025 | Stop Spinning Your Wheels on EoE
Drs. Dellon and Dickstein host a Symposium where audience members solve puzzles to uncover cutting-edge knowledge of eosinophilic esophagitis (EoE). This event is neither sponsored by nor endorsed by ACG.
Type 2 Inflammation
In this video from the 2024 Society for Pediatric Dermatology Symposium held in Toronto, Canada, Dr. Peter Lio, MD and Dr. Amy Paller, MD discusses the multifaceted nature of atopic diseases, including environmental triggers, key Type 2 inflammatory mechanisms, and associated health risks, to understand the importance of early intervention in managing and potentially modifying disease progression.
ESPD 2024 | Atopic Dermatitis in Children: Can Early Therapeutic Intervention Shape Disease Course?
This symposium illustrated the ways type 2inflammation contributes to atopic dermatitis (AD) disease pathogenesis within and beyond the skin, discussed the importance of early intervention in children with AD, and explored the potential for disease modification. The program concluded with a review of the latest clinical and real-world data on advanced systemic treatments for children with AD.
ADVENT at EAPS 2024
The ADVENT program will present a symposium to discuss diagnosis, pathophysiology, comorbidities of atopic dermatitis in children, as well as emerging treatment options for management of atopic dermatitis (AD) in children, who are candidates for systemic therapy at the 2024 European Academy of Paediatric Societies (EAPS) Congress.
ADVENT at ESPGHAN 2025 | Unlocking Better Outcomes: Strategies for Early Diagnosis and Effective Management in Pediatric EoE Patients
In support of World Eosinophilic Esophagitis Day, this ADVENT symposium features pediatric gastroenterology experts Dr Carolina Gutiérrez Junquera and Dr Christos Tzivinikos where they discuss the importance of early identification and management of pediatric EoE to improve long-term outcomes. They highlight clinical data and discuss their practical experiences with pediatric EoE, including their perspectives on co-occurring type 2 inflammatory diseases, the chronic nature of EoE, and the future of EoE research and therapeutic development.
What Went Wrong? How Dysregulated Type 2 Immunity Contributes to AD, PN, CSU, and BP
The March 2025 ADVENT symposium in Orlando, Florida brought together 4 dermatology experts to explore the evolving science of type 2 inflammation. Type 2 inflammation plays a central role in the pathophysiology of multiple dermatological diseases, driving chronic immune dysregulation that affects patients with atopic dermatitis (AD) prurigo nodularis (PN), chronic spontaneous urticaria (CSU) and bullous pemphigoid (BP). Understanding the mechanisms behind type 2 inflammation is key to advancing care and improving patient quality of life.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Join experts Mario Castro, Nicola Hanania, and Stephanie Christenson for an educational symposium on the real-world impact of underlying type 2 inflammation on the patient burden of asthma and COPD.
ADVENT at Diversity in Dermatology 2024 | Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Join Drs Sarina Elmariah and Mona Shahriari as they discuss the diagnostic considerations for atopic dermatitis and prurigo nodularis and uncovered how clinical signs and itch in these diseases are impacted by type 2 inflammation.
UEG 2025 | Understanding Type 2 Inflammation in EoE: A Case-Based Discussion
Profs. Greuter, Savarino, and Giordano discuss best practices for EoE identification, multidimensional EoE assessment, and transition of care.
